“The numbers are unprecedented,” Rasmus Beck Hansen, CEO of Airfinity, told the Financial Times.
More fear campaigns = more revenue streams.
After a breakout year, Moderna sees strong reason to believe 2021 won’t be a one-off boom year. That’s thanks to the predicted need for booster shots and additional supply deals coupled with stronger pricing power, Jefferies analysts wrote to clients Thursday following a conversation with CEO Stéphane Bancel.
The Jefferies team thinks Moderna could drive $15 billion in 2022 revenues, with an upper limit of $30 billion. Where the company lands will depend on how the pandemic progresses, fear of infection and whether the company can produce future products, like a combo shot against COVID and the flu.
7:24 am on October 27, 2021